These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 10458264)

  • 1. Increased HER2 with U.S. Food and Drug Administration-approved antibody.
    Roche PC; Ingle JN
    J Clin Oncol; 1999 Jan; 17(1):434. PubMed ID: 10458264
    [No Abstract]   [Full Text] [Related]  

  • 2. More than one way to look for HER2.
    Check W
    CAP Today; 1999 Mar; 13(3):1, 40-2, 46, passim. PubMed ID: 10350906
    [No Abstract]   [Full Text] [Related]  

  • 3. Chemotherapy and herceptin for HER2(+) metastatic breast cancer: the best drug?
    Livingston RB; Esteva FJ
    Oncologist; 2001; 6(4):315-6. PubMed ID: 11524548
    [No Abstract]   [Full Text] [Related]  

  • 4. HER2 status and benefit from adjuvant trastuzumab in breast cancer.
    Paik S; Kim C; Wolmark N
    N Engl J Med; 2008 Mar; 358(13):1409-11. PubMed ID: 18367751
    [No Abstract]   [Full Text] [Related]  

  • 5. Trastuzumab and beyond: New possibilities for the treatment of HER2-positive breast cancer.
    Morris SR; Carey LA
    Oncology (Williston Park); 2006 Dec; 20(14):1763-71; discussion 1771-2, 1774-6. PubMed ID: 17263127
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Trastuzumab--mechanism of action and use in clinical practice.
    Hudis CA
    N Engl J Med; 2007 Jul; 357(1):39-51. PubMed ID: 17611206
    [No Abstract]   [Full Text] [Related]  

  • 7. Drug update: trastuzumab: anti-HER2 antibody for treatment of metastatic breast cancer.
    Wong WM
    Cancer Pract; 1999; 7(1):48-50. PubMed ID: 9893005
    [No Abstract]   [Full Text] [Related]  

  • 8. Is trastuzumab active following conventional adjuvant chemotherapy in HER2-positive early breast cancer?
    Seidman AD
    Nat Clin Pract Oncol; 2006 Apr; 3(4):178-9. PubMed ID: 16596138
    [No Abstract]   [Full Text] [Related]  

  • 9. Experts debate value of HER2 testing methods.
    Nelson NJ
    J Natl Cancer Inst; 2000 Feb; 92(4):292-4. PubMed ID: 10675369
    [No Abstract]   [Full Text] [Related]  

  • 10. HER2 testing, adjuvant trastuzumab use and results. Our experience in South Wales.
    Webster R; Palaniappan N; Abraham J; Bertelli G; Jasani B; Barrett-Lee P
    Clin Oncol (R Coll Radiol); 2010 Dec; 22(10):894. PubMed ID: 20708911
    [No Abstract]   [Full Text] [Related]  

  • 11. Overview of the trastuzumab (Herceptin) anti-HER2 monoclonal antibody clinical program in HER2-overexpressing metastatic breast cancer. Herceptin Multinational Investigator Study Group.
    Shak S
    Semin Oncol; 1999 Aug; 26(4 Suppl 12):71-7. PubMed ID: 10482196
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapy of metastatic breast cancer with humanized antibodies against the HER2 receptor protein.
    Schaller G; Bangemann N; Becker C; Bühler H; Opri F; Weitzel HK
    J Cancer Res Clin Oncol; 1999; 125(8-9):520-4. PubMed ID: 10480346
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer.
    Goldenberg MM
    Clin Ther; 1999 Feb; 21(2):309-18. PubMed ID: 10211534
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trastuzumab administration associated with change in HER2 status.
    Dawood S; Resetkova E; Gonzalez-Angulo AM
    Clin Breast Cancer; 2008 Aug; 8(4):366-9. PubMed ID: 18757266
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Response of metastatic breast cancer to trastuzumab?
    Barnes DM; Miles DW
    Lancet; 2000 Jan; 355(9199):160-1. PubMed ID: 10675110
    [No Abstract]   [Full Text] [Related]  

  • 16. Controversies in the use of adjuvant trastuzumab (Herceptin).
    Chowdhury S; Pickering L; Ellis P
    J Br Menopause Soc; 2006 Dec; 12(4):172-4. PubMed ID: 17178019
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A case with HER2-overexpressing breast cancer completely responded to humanized anti-HER2 monoclonal antibody.
    Ohta M; Tokuda Y; Suzuki Y; Kubota M; Watanabe T; Fujii H; Sasaki Y; Niwa T; Makuuchi H; Tajima T
    Jpn J Clin Oncol; 2001 Nov; 31(11):553-6. PubMed ID: 11773264
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Trastuzumab. Monoclonal antibody for the treatment of breast cancer].
    Heinzl S
    Med Monatsschr Pharm; 2000 Nov; 23(11):350-2. PubMed ID: 11103587
    [No Abstract]   [Full Text] [Related]  

  • 19. [Herceptin and its therapeutic strategy in patients with breast cancer overexpressing HER2].
    Tajima T; Suzuki Y; Tokuda Y
    Gan To Kagaku Ryoho; 2002 Jul; 29(7):1132-7. PubMed ID: 12145992
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improved prognosis by trastuzumab of women with HER2-positive breast cancer compared with those with HER2-negative disease.
    Ferretti G; Fabi A; Felici A; Papaldo P
    J Clin Oncol; 2010 Jul; 28(20):e337; author reply e338-9. PubMed ID: 20479395
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.